NEURL1

Across TCGA pan-cancer cohorts, NEURL1 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated NEURL1 data layer compared with 28 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher NEURL1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated NEURL1 expression acts as an unfavorable survival marker.

STAD, BLCA, and PRAD are the cancer types where NEURL1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	II,III,IV	0.003	0.660	<.001	18	view →
BLCA	DFS	Median	IV	0.090	0.469	.009	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
ACC	DFS	Median	All	0.140	0.666	.049	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

NEURL1–STAD (OS)

Open the STAD breakdown →